ArticleCureus2025
Inflammatory Markers as Predictors of Onset and Recovery of Olfactory and Gustatory Dysfunction in COVID-19 Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Olfactory and gustatory dysfunctions are widely recognized as characteristic manifestations of COVID-19. However, the relationship between disease severity, inflammatory markers, and the recovery of chemosensory functions remains unclear, particularly in hospitalized patients. This study aimed to evaluate predictive hematological and radiological factors associated with the development and recovery of olfactory and gustatory dysfunction in COVID-19 patients. Methodology This prospective, observational study included 96 hospitalized patients diagnosed with COVID-19 via polymerase chain reaction testing between September 2020 and January 2021. A total of 53 patients with new-onset olfactory and/or gustatory dysfunction and 43 control subjects were selected through online randomization. Visual Analog Scale (VAS) scores were used to assess symptom severity and recovery. Hematological and inflammatory parameters, including neutrophil-to-lymphocyte ratio (NLR), corrected NLR, neutrophil-to-monocyte ratio (NMR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and procalcitonin levels, were analyzed. Thorax CT scores were used to determine disease severity. Follow-up evaluations were conducted by telephone at 90 days post-discharge to reassess VAS scores and recovery status. Results Olfactory loss was present in 42 (43.7%) patients, and taste loss in 44 (45.8%) patients. Olfactory dysfunction was significantly associated with age and higher thorax CT scores (p < 0.05). Procalcitonin and CRP levels were significantly associated with the development of both olfactory and gustatory dysfunction (p < 0.05). Lower NLR, d-NLR, NMR, and PLR values were strong predictors of recovery. At 90-day follow-up, 66.7% of patients with anosmia achieved complete recovery, 30.9% showed partial improvement, and 2.4% reported no recovery. All patients with taste impairment recovered (75% complete, 25% partial). Chemosensory dysfunction was more common in patients with milder disease severity. Conclusions Olfactory and gustatory dysfunctions are more prevalent in patients with milder COVID-19 and lower inflammatory burden. Elevated inflammatory markers and severe thoracic involvement were inversely associated with the development and recovery of chemosensory dysfunction. These findings suggest that systemic inflammation may play a detrimental role in neural recovery of chemosensory pathways and highlight the prognostic value of hematological markers in COVID-19 symptom monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.